By Tom Zanki ( April 7, 2015, 5:21 PM EDT) -- Liver disease treatment developer Intercept Pharmaceuticals Inc. raised about $366.8 million through a follow-on stock offering, money that the company on Monday said will fund development of its pipeline and expand manufacturing, joining a wave of life science companies tapping public markets....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.